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Abstract 19	
In vitro methods are commonly used in order to estimate the extent of systemic absorption of 20	
chemicals through skin. Due to the wide variability of experimental procedures, types of skin 21	
and data analytical methods, the resulting permeation measures varies significantly between 22	
laboratories and individuals. Inter-laboratory and inter-individual variations with the in vitro 23	
measures of skin permeation lead to unreliable extrapolations to in vivo situations. This 24	
investigation aimed at a comprehensive assessment of the available data and development of 25	
validated models for in vitro skin flux of chemicals under various experimental and vehicle 26	
conditions. 27	
Following an exhaustive literature review, the human skin flux data were collated and 28	
combined with those from EDETOX database resulting in a dataset of a total of 536 flux 29	
reports. Quantitative Structure-Activity Relationship techniques combined with data mining 30	
tools were used to develop models incorporating the effects of permeant molecular structure, 31	
properties of the vehicle, and the experimental conditions including the membrane thickness, 32	
finite/infinite exposure, skin pre-hydration and occlusion. 33	
The work resulted in statistically valid models for estimation of the skin flux from varying 34	
experimental conditions, including relevant real-world mixture exposure scenarios. The 35	
models indicated that the most prominent factors influencing flux values were the donor 36	
concentration, lipophilicity, size and polarity of the penetrant, and the melting and boiling 37	
points of the vehicle, with skin occlusion playing significant role in a non-linear way. The 38	
models will aid assessment of the utility of dermal absorption data collected under different 39	
conditions with broad implications on transdermal delivery research. 40	
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 44	
1. Introduction 45	
Skin is in continuous contact with exogenous molecules. Skin’s essential role is to protect the 46	
body from absorption of exogenous toxic material such as pesticides that target toxicological 47	
endpoints and can have local and systemic effects (Nielsen et al, 2004). Therefore, the 48	
European Commission program, REACH, requires extensive risk assessments of all existing 49	
chemicals, including exposure via dermal contact (Commission of the European 50	
Communities, 2003). Skin is also the focus of research by drug formulators as a site of drug 51	
administration, both for local dermatologic conditions as well as for systemic delivery due to 52	
the advantages it may offer over other routes of drug delivery (Barry, 2007).  53	
A vast number of studies in the past have compared the in vitro and in vivo methods for 54	
measuring dermal absorption and have come to the conclusion that properly conducted in 55	
vitro measurements can be used to predict in vivo absorption (OECD, 2004a). The OECD 56	
Test Guidelines 428 has also confirmed that in vitro studies can predict in vivo absorption 57	
when the correct methodology for both tests is used. In vitro methods can vary greatly in 58	
terms of the source of skin samples, experimental procedures, and the resulting 59	
measurements. These guidelines are flexible in terms of the use of animal or human skin 60	
samples (OECD, 2004a, 2004b). In the literature, many of the reported data pertains to the 61	
experiments using artificial skin membranes that mimic human skin. In terms of the human 62	
skin samples, the skin can be cadaver human skin or surgically removed skin which may be 63	
used fresh as viable skin or after certain period of freezing. These are all sources of 64	
variability in the reported results. For example, the absorption of benzoic acid and para-65	
aminobenzoic acid were significantly greater in nonviable, compared with viable, 66	
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metabolically active hairless guinea pig skin (Nathan et al., 1990). Moreover skin samples 67	
can be full thickness or dermatomed with varying thicknesses (Wilkinson et al., 2006). 68	
Apart from the skin sample, the experimental procedures can also influence the results of the 69	
in vitro tests. For example, stratum corneum can significantly change its dimensions when 70	
exposed for long periods to water (Bouwstra et al., 2003). Experimental approaches vary 71	
from studies employing pre-hydrated skin samples, to those using infinite doses which lead to 72	
the skin hydration during the period of the experiment, or studies using occlusion of the skin 73	
which may lead to some levels of hydration during the experiment, or those employing finite 74	
dosing without occlusion which limits the skin hydration. Skin occlusion has been found to 75	
enhance the percutaneous absorption of many, but not all topically applied compounds 76	
(reviewed by Zhai & Maibach (2001)). On the other hand, unoccluded conditions can 77	
simulate the normal exposure situations in everyday life. However, volatile compounds may 78	
evaporate under unoccluded conditions and infinite dosing can only take place under 79	
occluded conditions (Kligman, 1983; Bronaugh & Stewart, 1985; Baker, 1986). According to 80	
OECD (OECD, 2004b), for finite dose experiments, a dose of 1-5 mg/cm2 or 10 μl/cm2 81	
should be spread on the skin surface and for infinite dose experiments, a dose higher than 10 82	
mg/cm2 or 100 μl/cm2 is needed in order to obtain steady state conditions from which the flux 83	
and kp can be calculated. In the literature, a full spectrum of application doses can be found 84	
with varying duration of exposure and sampling time.  85	
The inter- and intra-laboratory variation in in vitro percutaneous absorption methodology has 86	
been investigated to some extent in the past. In a recent study by van de Sandt et al. (2004) 87	
the in vitro absorption of several compounds through human and rat skin were determined in 88	
different laboratories. In all laboratories the studies were undertaken according to detailed 89	
protocols of dose, exposure time, vehicle, receptor fluid, preparation of membranes and 90	
analysis. Results of this study showed noticeable differences that may be attributed to the 91	
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inter-individual variability in absorption between samples of human skin and differences in 92	
skin site and source. Skin thickness only slightly influenced the absorption of benzoic acid 93	
and caffeine; however the maximum absorption rate of the most lipophilic compound, 94	
testosterone, was clearly higher in laboratories using thin, dermatomed skin membranes. 95	
A vehicle can play a very important role in the penetration of a chemical through the skin. 96	
Solubility of a chemical is different in different vehicles hence resulting in different flux and 97	
kp values due to varying levels of saturation (Roberts et al, 2002). A vehicle can promote the 98	
penetration of a chemical by having low solubility, in this way a chemical will not be retained 99	
in the vehicle (Baker, 1986). In case in the vehicle there are components that can interact with 100	
the intercellular lipids of the SC then it is possible that permeation may be enhanced or 101	
suppressed (Davis et al., 2002).  Formulation ingredients can alter the skin penetration of a 102	
compound by affecting the barrier properties of the skin or by changing the partitioning of the 103	
compound into the SC. The effect of mixture/formulation components on the skin penetration 104	
of a compound depends on the nature of the component, i.e. its chemical structure and 105	
physicochemical properties. The relationship between chemical structures of the formulation 106	
ingredients and the skin penetration modification can be studied quantitatively using 107	
Quantitative Structure–Activity Relationship (QSAR) techniques (Ghafourian et al., 2004; 108	
2010a, 2010b; Riviere and Brooks, 2005, 2011). 109	
As an integral part of the human health risk assessment of chemicals and also to be able to aid 110	
drug delivery through skin, it is essential to be able to estimate absorption of chemicals via 111	
the dermal route. This is because despite the requirement by REACH for extensive risk 112	
assessment of chemicals, it is not practical to measure dermal absorption of the many 113	
thousands of industrial chemicals. In reality, estimation of skin absorption is complicated due 114	
to the inconsistency of the methods and therefore the inconsistent results of in vitro/ in vivo 115	
tests. The inter-laboratory and inter-individual variations are often high (Van de Sandt et al., 116	
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2004, Chilcott et al., 2005) which may be explained by the huge variety of methods and test 117	
systems used for skin permeation experiments. Moreover, methods of calculation and 118	
interpretation of results from the complex experimental set-up also varies (Henning et al., 119	
2009).  The aim of this study was to investigate the effects of experimental conditions such as 120	
membrane thickness, occlusion, hydration, vehicle ingredients and mode of exposure (finite 121	
or infinite dosing) on the skin permeation flux. This was achieved through the use of 122	
statistical techniques employing a large dataset extracted from EDETOX database and 123	
collated from more recent publications. The dataset was large enough to investigate 124	
statistically the effects of these variable experimental conditions combined with QSAR 125	
linking the skin flux to the chemical structures of the penetrants and the physico-chemical 126	
properties of the vehicle mixtures. 127	
2. Methods 128	
2.1. The dataset 129	
The in vitro flux of chemicals from human skin measured by flow-through or static cells were 130	
obtained from the recent literature (2001-2010) and EDETOX (Evaluations and Predictions 131	
of Dermal Absorption of Toxic Chemicals) database (EDETOX, 2010). The compiled data is 132	
available as Supplementary Material I. The EDETOX database contains data from in vitro 133	
and in vivo percutaneous penetration studies involving use of different species, cell types and 134	
chemicals with a total of 2501 records taken from 341 penetration studies. The EDETOX 135	
database gave information about chemical name, vehicle used, origin of the skin sample, 136	
membrane thickness, exposure time, length of study, percentage of dose absorbed, percentage 137	
recovery, flux, permeation rate (kp), lag time, where available, and the source publications. 138	
Further information with regards to the hydration state, occlusion condition, the volume 139	
applied (µl/cm2), dose applied (µg/cm2) and donor concentration (µg/ml) was added to the 140	
dataset by careful inspection of the original publications.  141	
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Following an exhaustive literature survey, data from recent publications (2001-2010) was 142	
added to the dataset extracted from EDETOX database. The literature survey was performed 143	
in the Web of Knowledge with the key worlds; skin absorption, skin penetration, skin 144	
permeation, skin permeability, dermal absorption, dermal penetration, dermal permeation and 145	
dermal permeability. From resulting 1800 publications all human in vitro data were extracted.  146	
Data concerning the pre-treated skin samples with a solvent or a penetration enhancer were 147	
discarded but pre-treatment with water (hydration) was allowed in the dataset. Absorption 148	
measurements from commercial mixtures with unknown constituents or complicated 149	
formulations such as liposomes and emulsions were not used. The final working dataset 150	
consisted of 536 flux reports containing 272 unique chemicals. The chemicals were either 151	
applied as neat (around 10% of the data) or formulated in simple mixtures with the majority 152	
of vehicles containing water as a constituent. In a few cases that the formulations were gels, 153	
the percentage of constituents were known. In majority of cases the exposure time was 24 h, 154	
but it varied from 0.167 to 336 h, and the sampling time between 0.167 and 336 h. The 155	
composition of the receptor fluid could vary to allow different additives, pH or solvent types. 156	
In many cases, the finite or infinite dosing conditions were explicitly specified in the 157	
literature. In other cases, if the application volume was above 100µl it was taken as ‘infinite’, 158	
if donor volume was between 50-100µl then provided that the percentage absorbed was  less 159	
than 20% it was considered as ‘infinite’ or otherwise a ‘finite’ application. An indicator 160	
variable was generated to indicate finite or infinite dosing in the statistical analyses with the 161	
values of 2 for finite and 1 for infinite dosing. Experimental conditions under which flux was 162	
measured were explored further and whether the skin was hydrated prior to the experiment 163	
(minimum of 1 hr hydration) and whether the donor compartment was occluded was recorded 164	
in the dataset. In order to incorporate these in statistical analysis, states of pre-hydration or 165	
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occlusion were given a value of ‘1’ where skin was hydrated or occluded and ‘0’ when the 166	
skin was not pre-hydrated or occluded. 167	
In the dataset the preparation of the skin may vary from full thickness or dermatomed skin, to 168	
epidermal membranes. Skin thickness measurements were specified in many publications in 169	
mm. If only a description was provided in the literature, the full thickness skin was taken as 2 170	
mm, epidermis as 0.8 mm and SC as 0.2 mm thick.  171	
2.2. Molecular descriptors of permeants: 172	
Simplified Molecular Input Line Entry Specifications (SMILES) of penetrants were obtained 173	
online from ChemSpider (2010), PubChem (2010), and Sigma-Aldrich (2010). If the 174	
compound structure was not available in these databases, reference books or ChemBioFinder 175	
(2010) were used to find the molecular structure, then the structure was drawn in 176	
ACD/ChemSketch software (Advanced Chemistry Development, Inc., Canada) and SMILES 177	
codes were obtained. The molecular descriptors (375) were calculated using ACD labs/LogD 178	
Suite version 12.01 (Advanced Chemistry Development, Inc., Canada) and Molecular 179	
Operating Environment (MOE) version 2011.10 (Chemical Computing Group Inc., Canada). 180	
The molecular descriptors included physical properties (e.g. partition coefficient and 181	
molecular weight), subdivided surface areas, atom and bond counts, molecular connectivity 182	
and kappa shape indexes, adjacency and distance matrix descriptors, partial charge 183	
descriptors, potential energy descriptors, MOPAC descriptors, and conformation dependent 184	
charge descriptors. 185	
2.3. Properties of the mixture (vehicle): 186	
The physico-chemical properties of mixture components such as boiling point, melting point, 187	
density, log P, and solubility were obtained through SRC PhysProp database (2010), Sigma 188	
Aldrich website (2010), and ChemSpider (2010). For pharmaceutical excipients such as 189	
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polyethyleneglycols (PEGs), petrolatum and mineral oil the properties were obtained from 190	
Rowe et al (2009). Average of the physicochemical properties for every solvent mixture was 191	
calculated for the liquid ingredients, e.g. boiling point of the vehicle. The effect of solid 192	
solutes (including the permeants) on boiling and melting points were calculated using the 193	
principles of the colligative properties (Sinko et al 2011). Therefore, boiling point elevation 194	
(ΔΤb) and freezing point depression (ΔΤf) due to the dissolved material can be calculated by 195	
equations (1) and (2) respectively. 196	
ΔΤb = molality * Kb * i  (1) 197	
ΔΤf = molality * Kf * i (2)  198	
In equation (1) and (2), Kb and Kf are ebullioscopic and cryoscopic constants specific for the 199	
solvent and i is Van‘t Hoff factor. The ebullioscopic (Kb) and cryoscopic constant (Kf) were 200	
obtained from the literature (Moore, 1972) and were averaged for the solvent mixtures.  201	
2.4. Development and Validation of models: 202	
Logarithm of steady state flux showed normal distribution and therefore this was used for 203	
statistical analysis and development of the mathematical models. Before model development, 204	
the data were assessed using a simple semi-mechanistic model involving a linear relationship 205	
between log Flux and simple parameters such as donor concentration (as in Fick’s law of 206	
diffusion), partition coefficient and molecular size (as in Potts and Guy’s model (1992)) and 207	
an index of molecular polarity. After establishing a preliminary linear relationship, the 208	
outliers were identified and, where appropriate, the identified outliers were removed from the 209	
dataset.  210	
The dataset was sorted according to log Flux values and partitioned into training and test sets 211	
by taking every fourth compound as the test set compound, achieving the ratio of three to one 212	
for training and test sets. Two main methods were used for the development of QSAR models 213	
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and investigating the effect of experimental variables. These were stepwise regression 214	
analysis using MINITAB statistical software ver 15.1.0.0 and non-linear method of RT 215	
(Regression Trees) in STATISTICA Data Miner software 9.1. These methods can be 216	
considered as variable selection tools for the development of linear (stepwise regression) and 217	
non-linear (RT) models with best fit to the training set data. Each of these methods can also 218	
allow the user to manipulate the statistically selected variables. Therefore, interactive RT 219	
data-mining tool was utilised to evaluate the variables of experimental conditions for each 220	
split. In RT method, several stopping criteria were examined. These included either, the 221	
minimum number of 11, 22 and 40 compounds, or the minimum fraction of 0.05, 0.02 and 222	
0.01	to the total number of compounds for partitioning. The default values were used for the 223	
maximum number of levels set at 10 and the maximum number of nodes at 1000. For the V-224	
fold cross-validation, seed for random number generator was set to 1 and the v value to 10.  225	
In order to compare the validity of the RT and regression models, models were generated 226	
using training set compounds and the prediction accuracy was assessed by comparing the 227	
average error levels of the estimation of log flux for the test set compounds. The error 228	
criterion was Mean Absolute Error (MAE) calculated for the test set. 229	
 3. Results 230	
For the development of predictive models and investigation of the effects of various 231	
experimental, vehicle or permeant variables, the collated dataset was first refined and the 232	
outliers were removed. The investigation was then focused on the development of a series of 233	
models with specific emphasis on the descriptors of in vitro experimental conditions and 234	
vehicle properties. Finally the models were validated and compared in terms of the accuracy 235	
of the skin flux predictions.   236	
3.1 The dataset 237	
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The collated dataset comprised work reported in a wide range of literature where the skin 238	
permeation measurements could pursue a large variety of goals ranging from in vivo / in vitro 239	
correlation studies (Dick et al., 1995) to pharmaceutical formulation optimisation (Dias et al., 240	
1999) which could include chemical enhancers (Patil et al., 1996). Furthermore, a large 241	
volume of the literature concerns the study of the effect of experimental conditions such as 242	
the skin type and area of the skin (Wilkinson & Williams, 2002), pH (Sznitowska et al., 243	
2001), mixture components (Santos et al., 2010), and receptor phase composition (Surber et 244	
al., 1991) on the in vitro absorption of compounds. Therefore large inter-laboratory and inter-245	
individual variations are very common. In the current exercise, a dataset with best internal 246	
consistency is required in order to investigate the effects of some of the variable experimental 247	
conditions as well as the vehicle and the permeant chemical structures. Therefore, the dataset 248	
was initially assessed through the use of a simple semi-mechanistic model and the extreme 249	
outliers were identified. In accordance with the Fick’s Law of diffusion and the well-accepted 250	
model of Potts and Guy (1992), this initial model for flux was formulated to comprise donor 251	
concentration (according to Fick’s Law of diffusion), a size descriptor and lipophilicity index 252	
(log P). In addition a polarity descriptor was also incorporated in the model as informed by 253	
previous studies (Tayar et al., 1991; Liou et al 2009). Multiple regression analysis was used 254	
to fit the data and only the statistically significant parameters with P values below 0.05 were 255	
allowed in the model (equation (3)).  256	
log Flux = 1.63 + 0.000002 [Donor] – 2.83 PSA/SA – 0.00417 MV (3) 257	
S = 1.25, r2 = 0.376, N = 499, F = 99.5 258	
In equation (3), [Donor] is the donor concentration, PSA/SA is the polarity index represented 259	
by the ratio of polar surface area to the total surface area, and MV is the size descriptor, 260	
molar volume. It must be noted that despite the fact that lipophilicity of permeants is believed 261	
to be a major factor in skin permeation of compounds, in this case octanol/water partition 262	
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coefficient (log P) was not statistically significant and therefore not included in equation (3). 263	
Figure 1 shows the plot between observed and calculated log Flux by equation (3), with the 264	
regression line between these two showing an intercept of 0.000 and a coefficient of 1.00. 265	
Chemicals with standardised residuals greater than 1.5 and less than -1.5 were marked as 266	
outliers; these are highlighted in Figure 1(a). A list of these outliers and some explanations 267	
for their deviations has been provided in the Supplementary material I. Most notably, out of 268	
22 compounds, 9 are steroids with the flux values taken from Scheuplein et al (1969). These 269	
skin permeability measurements have been reported to be consistently lower than those 270	
measured by several other groups (Johnson et al 1995). The outliers were removed from 271	
subsequent analyses. 272	
 273	
3.2 The models developed by statistical variable selection  274	
Molecular descriptors of the penetrants, properties of the vehicles and indicator variables for 275	
experimental conditions of flux measurement, namely finite/infinite dosing, skin pre-276	
hydration, occlusion and also the skin thickness in mm were used in stepwise regression 277	
analysis and Regression Trees analysis. Donor concentration was the first (and the most 278	
significant) variable controlling the flux of various compounds as indicated by both statistical 279	
methods. Equation (4) is the linear regression model developed by stepwise regression 280	
analysis. Figure 2 shows RT model (1). A description of the parameters used in all models 281	
has been provided in the notation section. 282	
log Flux = - 1.92 + 0.000001 [Donor] - 0.00570 MW + 0.00235 BP-MP(mix) + 3.96 vsurf_G 283	
+ 0.0137 SlogP_VSA4 - 1.93 fiAB - 0.343 VAdjMa   (4) 284	
S = 0.948, r2 = 0.558, N = 454, F = 80.41 285	
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The parameters of equation (4) consists of donor concentration, a vehicle property 286	
representing the difference between boiling and melting points of the vehicle mixture (BP-287	
MP(mix)), and five other parameters representing molecular descriptors of the permeants.  288	
The model generated by RT consists of donor concentration and three molecular descriptors 289	
for the penetrants (Figure 2). Table 1 gives the statistical parameters of the RT model.  290	
 291	
3.3 Models incorporating the membrane thickness 292	
Skin thickness is thought to play a significant role in dermal absorption of chemicals. 293	
Permeation through viable full thickness skin membranes has been shown to be less than 294	
permeation through only the epidermis (Cnubben et al. 2002). The membrane thickness in the 295	
dataset varied between 0.2 for SC and 2 mm for the full thickness human skin. Membrane 296	
thickness (in mm) was incorporated in linear regression (equation (5)) and RT model (Figure 297	
3). 298	
logFlux = - 1.67 + 0.000001 [Donor] - 0.00561 MW + 0.0140 SlogP_VSA4 - 1.95 fiAB + 299	
0.00192 BP-MP(mix) + 3.82 vsurf_G - 0.312 VAdjMa - 0.201 Thickness (5) 300	
S = 0.943   r2 = 0.564 N = 454 F = 71.9   P < 0.001 301	
Although r2 of equation (5) shows only a slight improvement to equation (4), the thickness 302	
parameter is statistically significant in this equation (P = 0.014). Wilkinson et al. (2004, 303	
2006) studied the influence of skin thickness on percutaneous penetration using caffeine, 304	
testosterone, butoxyethanol and propoxur. They concluded that a complex relationship exists 305	
between skin thickness, lipophilicity of the penetrant, and percutaneous penetration and 306	
distribution. Therefore, due to the uneven effect of skin thickness on the penetration of 307	
different chemicals of varied lipophilicity (or other physicochemical properties), a linear 308	
relationship such as equation (5) cannot adequately represent the effect of thickness. 309	
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Accordingly, incorporation of skin thickness in the RT analysis could be more beneficial. In  310	
RT model (2) (Figure 3), this parameter was used in the first split and the tree was allowed to 311	
select other parameters of the highest statistical significance. The RT model involved skin 312	
thickness, donor concentration and four molecular descriptors of the penetrants. 313	
 314	
3.4 Models incorporating the finite or infinite dosing 315	
The dataset included in this work contained steady state and maximum flux obtained under 316	
finite and infinite dose exposures. In infinite dose, the concentration of the solution applied to 317	
the skin does not significantly change over time. Therefore a maximum flux can be achieved 318	
and maintained during the course of the experiment (steady state flux). However in finite 319	
dose exposures the amount of test preparation applied to the skin will reduce over time and 320	
therefore the maximum flux cannot be maintained. In order to incorporate the dose exposure 321	
condition, an indicator variable taking a value of 2 for finite and 1 for infinite condition was 322	
used. Out of 513 flux values with known exposure conditions, 143 and 370 were obtained 323	
under finite and infinite exposure conditions, respectively. The graph between observed log 324	
flux values and the log flux calculated by equation (4) indicates differing lines of best fit to 325	
the data obtained under infinite or finite dose exposures (Figure 1(b)). These regression lines 326	
were compared using general linear model (GLM). The results, reported in Table 2, indicate 327	
statistically different slopes and intercepts for finite and infinite exposures. Moreover, when 328	
included in the regression analysis, the indicator variable for finite/ infinite dose was 329	
statistically significant with a P value of 0.000 (equation (6)). 330	
Log Flux = - 1.08 + 0.000001 [Donor] - 0.00592 Weight + 0.00992 SlogP_VSA4 - 1.85 fiAB 331	
+ 0.00230 BP-MP(mix) + 3.55 vsurf_G - 0.293 VadjMa - 0.391 Infinite/Finite  (6) 332	
S = 0.936  r2 = 0.572  N = 453  F = 74.1  P < 0.001 333	
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The negative coefficient of Infinite/Finite (indicator variable) indicates higher flux values 334	
when measured under infinite dose exposures. 335	
RT analysis with the inclusion of this indicator variable as the first partitioning parameter was 336	
performed using Interactive Trees application in STATISTICA. The RT model (RT (3)) 337	
indicated somewhat higher average flux for infinite exposure experiments (Figure 4).  338	
 339	
3.5 Models incorporating the skin pre-hydration 340	
The stratum corneum normally contains 5-20% water, but it can contain upto 50% water 341	
when hydrated. Hydration can affect the permeability of the skin to chemicals (Roberts & 342	
Walker, 1993). Pre-hydration of the skin before the start of the experiment is very common in 343	
infinite dose procedures in order to maintain the consistency of the membrane during the 344	
course of the experiment. In this dataset, 187 data points used pre-hydrated skin and 317 data 345	
points employed dry skin. Figure 1(c) identifies the lines of best fit to the data obtained with 346	
pre-hydrated or dry skin. Comparing these lines by GLM (Table 2) shows that pre-hydration 347	
of the skin does not affect the slope of the line, although the intercepts are statistically 348	
different. When used in combination with descriptors of equation (4), the indicator variable 349	
for skin pre-hydration is not statistically significant at P<0.05. However, with a P value of 350	
0.077, pre-hydration of skin has a positive effect on skin flux. 351	
One reason for the insignificant effect of pre-hydration could be attributed to the fact that at 352	
least with infinite dose experiments, stratum corneum can quickly hydrate during the course 353	
of the experiment. Moreover, even in finite dose experiments, many studies are conducted 354	
under occluded conditions, which may lead to some levels of hydration. On the other hand, 355	
the extent of the hydration-related permeability change for different chemicals is not well 356	
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elucidated. For example, it has been shown that the increase of hydration due to occluded 357	
conditions does not always guarantee an increase in penetration rates (Bucks et al. 1991).  358	
In conclusion, as with membrane thickness, hydration of skin may have different levels of 359	
effects on the flux of compounds with varying physicochemical properties. Therefore, the 360	
effect is expected to be captured better in the non-linear models such as RT. The indicator 361	
variable for skin pre-hydration was incorporated as the first partitioning parameter in 362	
interactive RT analysis. The model (RT(4)) indicated higher average flux from pre-hydrated 363	
skin than from dry skin with the average log flux difference of 0.144 (Figure 5).  364	
 365	
3.6 Models incorporating the occlusion state of the skin 366	
Occlusion of the skin can lead to the gradual hydration of the skin during the course of the in 367	
vitro tests even during finite exposures where only a small volume of dose is applied. 368	
Therefore, as with hydration, flux values of various compounds is expected to be affected by 369	
occlusion of the skin. Out of 481 flux values with reported occlusion condition, 287 and 194 370	
were performed under occluded and non-occluded conditions respectively. Indicator variable 371	
for occlusion was not statistically significant when incorporated in the regression analysis 372	
(P=0.506). The graph between observed and calculated log Flux using equation (4) gives 373	
similar slopes but differing intercepts for the data obtained under occluded or non-occluded 374	
conditions (Figure not shown, see GLM results in Table 2). To explore the effect of occlusion 375	
further, it was incorporated in RT analysis. The resulting RT model (Figure 6, RT (5)) 376	
indicates that the average flux obtained under occluded conditions is higher than the average 377	
flux measured under non-occluded conditions by 0.66 log units.  378	
 379	
3.7. Models incorporating the vehicle effects 380	
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Stepwise regression analysis selected the difference between boiling and melting points of the 381	
vehicle mixtures to represent the effect of vehicle on the flux (equation (4)). However, a 382	
vehicle descriptor is missing from most RT models with the exception of RT (4) which 383	
includes a vehicle descriptor (boiling point of vehicles). The effect of vehicle properties on 384	
the flux was further analysed by incorporating boiling point, melting point and the gap 385	
between these in the interactive RT. The model obtained using BP-MP(mix) (Presented as RT 386	
model (6) in Figure 7) had the lowest standard error. According to this model, flux is higher 387	
if the donor mixture has a larger gap between the melting and boiling points of the vehicle. 388	
Table 1 shows that RT (6) has the lowest mean absolute error amongst all RT models. This 389	
may indicate the high significance of the vehicle properties in the skin absorption. 390	
 391	
3.8. Validity and Reliability of the models 392	
In any QSAR modelling, it is essential to examine the validity of the models for future 393	
predictions. This is also important due to the large number of molecular descriptors that are 394	
initially considered for the descriptor selection, which may result in chance correlations and 395	
poor generalisation (Konovalov et al., 2008). In this work, every effort have been made to 396	
assess the models by considering the interpretability of the models and agreement with the 397	
previous knowledge. Moreover, regression models (equations (4) – (6)) and RT models (1) – 398	
(6) were validated by using the regression equations and RT models developed for the 399	
training set for the estimation of the flux values of the test set. Table 3 gives the mean 400	
absolute error of log Flux estimation for the test set compounds and the number of test set 401	
compounds for which the models are able to provide the estimation. The lowest average error 402	
is achieved with RT model (5) followed by RT (4) and then regression equation (6) and RT 403	
(3).  404	
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4. Discussion 406	
Inter-laboratory and inter-individual variations are very common in the in vitro measures of 407	
skin permeation. This has been attributed to a number of experimental variables including 408	
differences in skin samples’ thickness, skin hydration, occlusion of the skin, infinite or finite 409	
dosing and vehicle ingredients. The dataset gathered here provided an excellent resource for 410	
development of QSAR models which also incorporate the effect of various experimental 411	
variables. The models can elucidate the effects of various parameters on the in vitro measures 412	
of skin permeation. The statistical analysis involved linear stepwise regression and non-linear 413	
regression tree analyses. Regression tree analysis has the advantage that it does not assume 414	
linearity in the relationship between the flux and any of the variables. The statistically 415	
selected parameters by these methods were donor concentration, several molecular 416	
descriptors of the permeants and, in case of stepwise regression, the difference between 417	
boiling and melting points of the donor mixtures (See equation (4) and Figure 2).  418	
The relevance of the donor concentration of the permeant to the flux is clear as the higher the 419	
concentration the higher the driving force and the flux according to Fick’s law of diffusion, 420	
and this can be observed in both the linear regression and RT models. In equation (4), the 421	
difference between the boiling and the melting points of the donor mixture shows a positive 422	
effect on the flux. Ghafourian et al (2010a) had observed a similar effect previously for a 423	
different dataset that involved various combinations of five different vehicle ingredients and 424	
16 permeants. The reason for this effect can be attributed to the better penetration of low 425	
melting point vehicles carrying the drug along into and out of the skin (Monene et al., 2005). 426	
For example, the formation of eutectic mixtures between drug and some vehicles has been 427	
proposed as the reason for skin penetration enhancement by some terpenes (Stott et al., 428	
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1997). On the other hand, the magnitude of the gap between melting and boiling points 429	
indicates certain characteristics in the molecular structure as it is believed that more 430	
symmetrical molecules have higher melting points and lower boiling points (Slovokhotov et 431	
al., 2007). Presence of molecular weight of the permeants in equation (4) is in agreement with 432	
the model proposed by Potts and Guy (1992). The molecular descriptor vsurf_G represents 433	
the molecular globularity (Cruciani et al., 2000), and with a positive coefficient, indicates 434	
higher flux values of non-spherical molecules that may be elongated or planar shaped. 435	
SlogP_VSA4 is a lipophilicity descriptor for the permeants which is known to play a major 436	
role in skin permeation (Bouwman et al., 2008). FiAB is the fraction of ionization of 437	
molecules at pH 7.4. In the lipophilic environment of the stratum corneum ionized molecules 438	
are expected to permeate more slowly than unionized molecules (Watkinson et al., 2009). 439	
The last molecular descriptor of the permeant in equation (4) (VadjMa) represents the 440	
number of strong bonds (ionic, covalent, polar covalent). The number of strong bonds is 441	
related to the size of the molecule therefore the larger molecules are expected to have low 442	
permeation rates.  443	
Similarly, according to RT (1), the requirements of a high skin flux are high donor 444	
concentration, small positively charged molecular surface area (PEOE_VSA_POS), large 445	
surface area of non-acidic hydrogen bond acceptors such as ether and ketone groups 446	
(vsa_acc), with a complex effect of hydrophobic volume (vsurf-D6) probably indicating the 447	
negative effect of molecular size at nodes ID 4, 5, 14 and 15, and the positive effect of 448	
hydrophobicity at nodes ID 6, 7, 10 and 11. 449	
As one of the objectives of the investigation was to incorporate the effects of the in vitro 450	
experimental conditions in the models, further RT and linear regression models were 451	
developed with the incorporation of parameters such as skin thickness, dosing conditions and 452	
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states of pre-hydration or occlusion of the skin. This led to RT models (2) – (6) and equations 453	
(5) – (6), the statistical performance and the validity of which can be compared.  454	
Within the linear regression equations, the order of significance of the experimental variables, 455	
as deduced from the P-values, were BP-MP(mix) in equation (4), indicator variable for finite 456	
or infinite dosing in equation (6) (P=0.000), skin thickness in equation (5) (P=0.014), and 457	
pre-hydration (P=0.077), with occlusion of the skin not being significant (P>0.10). Validation 458	
of the models also revealed a lower average error (for test set) for the model incorporating 459	
mode of exposure as opposed to the skin thickness (Table 3).  460	
According to the mean absolute error of the calculated values (reported in Table 1), the order 461	
of significance of the non-linear RT models is models incorporating: BP-MP(mix), occlusion, 462	
pre-hydration, and mode of exposure. However, validation of these models indicated the 463	
highest validity of the model incorporating occlusion state of the skin (RT (5)) followed by 464	
the model incorporating both skin pre-hydration and boiling point of the donor phase (RT (4)) 465	
and then the model incorporating the mode of exposure (RT (3)) (see Table 3).	 This 466	
conclusion, in association with the fact that experimental parameters of occlusion and pre-467	
hydration perform better in non-linear models, indicate that occlusion and skin pre-hydration 468	
have important but complex and non-linear effects on the skin absorption.  469	
It has previously been observed that occlusion and skin hydration may affect the skin 470	
permeation of different permeants differently (Bucks et al. 1991). For example, comparing 471	
the skin permeability measure obtained from Fickian diffusion model and that obtained from 472	
the transient skin permeation profiles, Tang et al Tang et al (2002) reported significantly 473	
increased skin permeability due to hydration for highly hydrophilic compounds while skin 474	
permeation of lipophilic compounds were comparable between the hydrated and non-475	
hydrated states of skin. Similar nonlinear effects have also been reported for the effect of skin 476	
thickness on permeation of drugs with various lipophilicities (Wilkinson et al., 2004). The 477	
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effect of occlusion may be explained by gradual skin hydration, or evaporation of the volatile 478	
penetrants and/or the vehicles. In the study of Sartorelli et al. (2000) a 5 to 10 fold increase in 479	
permeability of the stratum corneum was noted when the skin was occluded.	In the study of 480	
Jung et al. (2003) where catechol was applied in ethanol, occluded conditions resulted in 78% 481	
of the applied dose permeating compared with 55% in non-occluded samples.  482	
Figures 2-7 show the RT models incorporating skin thickness (RT (2)), mode of exposure 483	
(RT (3)), pre-hydration (RT (4)), occlusion (RT (5)), and vehicle boiling and melting point 484	
gaps (RT (6)). RT model (2) indicated that the average log Flux with skin thickness of ≤1.21 485	
mm is much higher than with skin samples of >1.21 mm thick (average log flux of 1.124 and 486	
0.252 respectively). The model also indicates higher in vitro skin flux with large donor 487	
concentrations, low polarity index (indicated by high GCUT_PEOE_1), small positively 488	
charged molecular surface area (PEOE_VSA_POL), small hydrophilic volume	 (vsurf_W1) 489	
and small molecular size (chi1v_C). 490	
RT (3) indicates that compounds will have higher in vitro flux values when applied in infinite 491	
doses, with high donor concentrations, and if they have high lipophilicity 492	
(GCUT_SLOGP_1), small molecular size (chi0 and GCUT_SMR_3) with high polarisability 493	
(SMR_VSA6) or hydrophilic surface (vsurf_CW3). According to RT (4), compounds with 494	
small molecular size (KierA1), applied in higher concentrations, especially those with small 495	
hydrophobic surface area (vsa_hyd), will be absorbed very well from pre-hydrated skin 496	
samples. Similarly, from (initially) dry skin samples, compounds with small molecular size 497	
(chi0v) applied in high concentrations are absorbed with the highest flux, while those applied 498	
in lower concentrations, with a small molecular size (wienerPath), having a high 499	
polarisability (GCUT_SMR_0), if administered in a low boiling point vehicle are absorbed 500	
the least. RT (5) indicates a higher flux from occluded skin samples for chemicals applied in 501	
high concentrations having a small molecular size (chiv_C), while those applied in low doses 502	
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are expected to have low flux values especially if the molecules have high hydrogen bonding 503	
donor capacity (vsurf_HB5). From non-occluded skin samples, compounds with relatively 504	
high solubility (logS) applied in high doses also show high flux values, while those with low 505	
solubility, large sum of positive atomic charges (leading to low relative positive charge, 506	
PEOE_RPC+) or low polar volume (vsurf_Wp2) show the least flux values. RT (6) shows 507	
that flux is higher if the donor mixture has a higher gap between melting and boiling points 508	
and the molecular size of the permeant is small (large chiv_C), especially if applied in higher 509	
concentrations. If BP-MP(mix) is small, then molecules with small molecular size (KierA1) 510	
still have higher flux values than the large molecular size compounds specially if applied in 511	
higher concentrations.  512	
It can be noted that skin thickness or the indicator variables for the experimental conditions, 513	
namely pre-hydration, finite/ infinite dosing or occlusion, are not selected by stepwise 514	
regression analysis (equation (4)) or regression tree (RT (1). Given the higher prediction 515	
accuracy of some of the models that incorporate experimental conditions, this may be 516	
attributed to the incorporation of extremely high number of permeant molecular descriptors in 517	
stepwise regression and RT analyses (a total of 375 descriptors) in comparison with the few 518	
variables of experimental conditions, leading to inadequate variable selection by these 519	
statistical methods.  520	
In conclusion, comparing all linear and nonlinear models (Table 3), it can be seen that the 521	
generally, RT models perform better in terms of the prediction accuracy for the test set. The 522	
lowest average error is achieved with RT model (5) followed by the RT (4) and then 523	
regression equation (6) and RT (3). The most valid model, RT (5) involves the occlusion 524	
indicator variable, donor concentration, and five permeant descriptors implying the negative 525	
effects of molecular size and hydrogen bonding donor ability on flux from occluded skin, and 526	
positive effect of aqueous solubility, and polar volume and negative effect of relative positive 527	
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charge when the skin is not occluded. It must be noted that the number of test compounds for 528	
which estimation has been made possible is different, depending on the availability of the 529	
model parameters. 530	
In both regression and RT models donor concentration of the permeant is the most important 531	
parameter related to the skin flux. This is expected since concentration is the driving force for 532	
passive diffusion of molecules across the skin. A variety of permeant parameters have been 533	
employed in the models, with majority implying the negative impacts of the large molecular 534	
size and hydrophilicity, while a certain level of lipophilicity and polarisability has been 535	
indicated as a positive effect on the flux. 536	
The statistical analyses and models reported in this work provide a suitable method for 537	
homogenizing the in vitro flux values measured under varying experimental and exposure 538	
conditions and will provide reasonable estimates of the flux values under other experimental 539	
conditions.  It is expected that the results will benefit in vivo estimations using the in vitro 540	
flux estimates. 541	
 542	
Notation  543	
 544	
Model 
parameters Description 
[donor] donor concentration (µg/ml) 
BP-MP(mix) difference between the boiling and melting points of the mixture (donor phase) 
chi0 Zero order molecular connectivity index a 
chi0v Zero order valence molecular connectivity index a 
chi1v_C First order carbon valence connectivity index a 
fiAB fraction of molecules ionized as anion and cation at pH 7.4 
GCUT_PEOE_1 
The GCUT descriptors are calculated from the eigenvalues of a 
modified graph distance adjacency matrix. Each ij entry of the 
adjacency matrix takes the value 1/sqr(dij) where dij is the (modified) 
graph distance between atoms i and j. The diagonal takes the value of 
the PEOE partial charges. The resulting eigenvalues are sorted and the 
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smallest, 1/3-ile, 2/3-ile and the largest eigenvalues are reported b 
GCUT_SLOGP_1 The GCUT descriptors using atomic contribution to logP instead of partial charge b 
GCUT_SMR_0 The GCUT descriptors using atomic contribution to molar refractivity using the instead of partial charge b 
GCUT_SMR_3 The GCUT descriptors using atomic contribution to molar refractivity instead of partial charge b 
Infinite/Finite Indicator variable indicating infinite or finite exposures taking a value of 2 for finite and 1 for infinite dosing 
KierA1 First alpha modified shape index, also correlated with molecular size a 
KierA3 
Third alpha modified shape index, informing centrality of branching 
with large values representing location of branching at the extremities 
of the molecule a 
Logs Log of the aqueous solubility (mol/L) calculated by MOE from an atom contribution linear atom type model b 
MW molecular weight 
Occlusion Indicator variable for occlusion of the skin during in vitro test 
PEOE_RPC+ Relative positive partial charge: the largest positive atomic partial charge divided by the sum of the positive partial charges b 
PEOE_VSA_POS  Total positive van der Waals surface area. This is the sum of the van der Waals surface area of atoms with non-negative partial charges b. 
Pre-hydration Indicator variable for pre-hydration of the skin prior to the in vitro test 
SlogP_VSA4 sum of van der Waals surface area of atoms with log P contributions in the range of (0.1-0.15) b 
SMR_VSA6 
 
Sum of the van der Waals surface area of atoms with atomic 
contribution to molar refractivity in the range (0.485, 0.56) b. 
Thickness Skin thickness 
VAdjMa vertex adjacency information which depends on the number of heavy-heavy bonds b 
vsa_acc 
Approximation to the sum of VDW surface areas of pure hydrogen 
bond acceptors (not counting acidic atoms and atoms that are both 
hydrogen bond donors and acceptors such as -OH) b. 
vsa_hyd Approximation to the sum of VDW surface areas of hydrophobic atoms b 
vsurf_CW3 
Capacity factor representing the ratio of the hydrophilic surface over 
the total molecular surface. These are calculated at eight different 
energy levels c 
vsurf_D6 Volume that can generate hydrophobic interactions. VolSurf computes hydrophobic descriptors at eight different energy levels c 
Vsurf_EWmin1 The lowest hydrophilic interaction energy 
vsurf_G The molecular globularity – how spherical a molecule is, where values above 1 is non-perfect spheres c 
vsurf_HB5 
H-bond donor capacity, representing the molecular envelope which 
can generate attractive H-donor interactions with carbonyl oxygen 
probe. The descriptors are computed at six different energy levels c. 
vsurf_W1 
Hydrophilic volume describing the molecular envelope which 
attractively interacts with water molecules at eight different energy 
levels c. 
vsurf_Wp2 Polar volume c 
wienerPath Wiener path number: half sum of all the distance matrix entries b 
26	
	
a: Hall and Kier (1991); b: MOE (2011); c: Cruciani et al. (2000) 545	
 546	
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Figure 1. Observed log Flux against calculated log Flux by equation (3); Figure 1(a) 725	
illustrates different groups: ‘+’ indicates the training set, ‘o’ indicates the test set and ‘•’ 726	
indicates the outliers; Figure 1(b) shows the lines of best fit for the data obtained under 727	
infinite (solid line) and finite (dashed line) dosing; Figure 1(c) shows the lines of best fit for 728	
the data obtained from pre-hydrated (dashed line) or dry (solid line) skin. 729	
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Figure 2. RT model (1), N is the number of data, Mu is the mean and Var is the variance of 734	
log Flux 735	
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Tree graph for log Flux
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Figure 3. RT model (2) incorporating membrane thickness for the first partitioning, N is the 739	
number of data points, Mu is the average and Var is the variance of log Flux 740	
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Figure 4. RT model (3) incorporating indicator variable for infinite or finite dose application, 742	
N is the number of data points, Mu is the average and Var is the variance of log Flux 743	
35	
	
Tree graph for log Flux
Num. of non-terminal nodes: 9,  Num. of terminal nodes: 10
Model: C&RT
ID=1 N=514
Mu=0.947
Var: 2.019
ID=8 N=317
Mu=0.913
Var: 2.204
ID=10 N=163
Mu=0.121
Var: 1.196
ID=12 N=103
Mu=0.532
Var: 1.179
ID=15 N=65
Mu=0.129
Var: 0.981
ID=11 N=126
Mu=2.179
Var: 0.781
ID=9 N=187
Mu=1.057
Var: 1.660
ID=20 N=105
Mu=1.855
Var: 0.930
ID=23 N=70
Mu=2.329
Var: 0.377
ID=14 N=38
Mu=1.222
Var=0.762
ID=16 N=35
Mu=-0.318
Var=0.635
ID=17 N=29
Mu=0.672
Var=0.897
ID=13 N=60
Mu=-0.585
Var=0.438
ID=18 N=88
Mu=2.527
Var=0.483
ID=19 N=38
Mu=1.375
Var=0.544
ID=22 N=35
Mu=0.907
Var=0.690
ID=24 N=34
Mu=2.766
Var=0.150
ID=25 N=36
Mu=1.915
Var=0.239
ID=21 N=82
Mu=0.036
Var=0.737
pre-Hydration
<= 0.500 > 0.500
[donor]
<= 67950 > 67950
weinerPath
<= 759.500 > 759.500
GCUT_SMR_0
<= -0.518 > -0.518
Bp
<= 99.594 > 99.594
chi0v
<= 5.558 > 5.558
KierA1
<= 9.569 > 9.569
[donor]
<= 33500 > 33500
vsa_hyd
<= 126.546 > 126.546
744	
Figure 5. RT model (4) incorporating indicator variable for skin pre-hydration for the first 745	
partitioning, N is the number of data points, Mu is the average and Var is the variance of log 746	
Flux. 747	
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Figure 6. RT model (5) incorporating occlusion in the first partitioning, N is the number of 749	
data points, Mu is the average and Var is the variance of log Flux. 750	
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Figure 7. RT model (6) incorporating BP-MP(mix) as the first parameter for partitioning, N is 752	
the number of data points, Mu is the average and Var is the variance of log Flux.  753	
  754	
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Table 1. Statistical parameters of RT models 
RT model Experimental Parameter MAE Risk Estimate 
(1) - 0.625 0.643 
(2) Skin thickness 0.638 0.676 
(3) Exposure type 0.628 0.655 
(4) Pre-hydration 0.597 0.569 
(5) Occlusion 0.587 0.585 
(6) BP-MP(mix) 0.552 0.041 
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